01.09.2022

The article is based on a press release from the PROTECT-trial partnership

The PROton versus photon Therapy for Esophageal Cancer – a Trimodality strategy (PROTECT) -trial is a large-scale, multi-institutional, randomized controlled clinical trial, that will compare the clinical outcomes of proton therapy and state-of-the-art photon radiotherapy for locally advanced esophageal cancer, with the goal of improving outcomes for this group of patients.

The PROTECT-trial consortium is a public-private collaboration that includes 12 proton therapy centers, 17 academic partners, two leading industry collaborators, and more than 30 clinical trial sites across eight countries. This project has received funding from the Innovative Medicines Initiative (IMI), the European Federation of Pharmaceutical Industries and Associations (EFPIA), IBA, and Varian, a Siemens Healthineers company.

An important aspect of the study is to improve patient selection for proton therapy in general by evaluating existing selection criteria and creating shared guidelines for reimbursement. The first patient has now been included in the clinical trial.

The grand-scale research project will be coordinated from Aarhus University and the DCPT.

Read more at protecttrial.eu